Cooper Companies’ (COO) “Neutral” Rating Reaffirmed at Bank of America

Cooper Companies (NASDAQ:COO)‘s stock had its “neutral” rating reissued by research analysts at Bank of America in a note issued to investors on Thursday, Benzinga reports. They presently have a $65.00 price target on the medical device company’s stock, down from their prior price target of $80.00. Bank of America‘s price objective would suggest a potential upside of 2.39% from the company’s current price.

A number of other analysts also recently weighed in on the stock. Stifel Nicolaus reduced their target price on shares of Cooper Companies from $95.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, June 5th. Citigroup reiterated a “neutral” rating and issued a $80.00 price target (up from $76.00) on shares of Cooper Companies in a research report on Thursday, August 13th. Wall Street Zen raised shares of Cooper Companies from a “hold” rating to a “buy” rating in a research note on Sunday, June 21st. Piper Sandler downgraded Cooper Companies from an “overweight” rating to a “neutral” rating and set a $59.00 price target on the stock. in a report on Thursday. Finally, BNP Paribas Exane reduced their price target on shares of Cooper Companies from $95.00 to $92.00 and set an “outperform” rating on the stock in a research note on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $75.27.

Cooper Companies Stock Down 6.2%

NASDAQ COO opened at $63.48 on Thursday. The stock has a market cap of $12.38 billion, a PE ratio of 53.80, a P/E/G ratio of 1.77 and a beta of 0.82. The company has a current ratio of 1.27, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23. Cooper Companies has a 12 month low of $58.89 and a 12 month high of $89.83. The stock’s 50 day moving average is $72.42 and its 200 day moving average is $70.02.

Cooper Companies (NASDAQ:COO) last released its earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.12 by $0.03. The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The company’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Research analysts predict that Cooper Companies will post 4.63 EPS for the current fiscal year.

Cooper Companies announced that its Board of Directors has authorized a share repurchase program on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the medical device company to repurchase up to 22.7% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Hedge Funds Weigh In On Cooper Companies

Several institutional investors and hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System grew its stake in Cooper Companies by 6,101.7% during the 2nd quarter. California State Teachers Retirement System now owns 19,460,014 shares of the medical device company’s stock worth $1,395,478,000 after buying an additional 19,146,230 shares during the last quarter. BlackRock Inc. purchased a new position in Cooper Companies during the second quarter valued at approximately $1,077,762,000. State Street Corp raised its position in shares of Cooper Companies by 2.4% in the fourth quarter. State Street Corp now owns 8,793,747 shares of the medical device company’s stock worth $720,736,000 after acquiring an additional 207,195 shares during the period. Wellington Management Group LLP lifted its position in shares of Cooper Companies by 332.9% during the 3rd quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock valued at $424,043,000 after buying an additional 4,756,178 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Cooper Companies by 58.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,028,821 shares of the medical device company’s stock worth $494,123,000 after buying an additional 2,231,568 shares during the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies reported fiscal third-quarter adjusted EPS of $1.15, ahead of the $1.11–$1.12 analyst consensus. Revenue reached approximately $1.066 billion, while free cash flow increased 66% to $273 million. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board expanded its share-repurchase authorization from $2 billion to $3 billion, potentially allowing the company to buy back as much as 22.7% of outstanding shares. Management also repurchased $339.1 million of stock during the quarter, supporting per-share value if executed effectively. CooperCompanies Completes Strategic Review
• Neutral Sentiment: GAAP EPS was $2.24, helped substantially by a $307.2 million discrete tax benefit related to the favorable completion of a U.K. tax examination. This benefit improves reported results but is not representative of recurring operating performance. CooperCompanies Reports Third-Quarter Results
• Negative Sentiment: CooperCompanies lowered fiscal 2026 adjusted EPS guidance to $4.51–$4.55, below the roughly $4.63 consensus, and set fourth-quarter EPS guidance at $1.05–$1.09 versus expectations near $1.20. Full-year revenue guidance of $4.229–$4.252 billion also implies modest growth.
• Negative Sentiment: The strategic review concluded that CooperSurgical will be retained because potential offers were not sufficiently attractive. Investors appear disappointed that the company did not unlock value through a sale, particularly amid fertility-related litigation costs and competitive pressure in the IUD market. Reasons Cooper Companies Stock Is Under Pressure

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.